Nuvectra Corp (NASDAQ:NVTR) CEO Scott F. Drees purchased 25,000 shares of the company’s stock in a transaction on Tuesday, March 14th. The shares were purchased at an average cost of $6.21 per share, with a total value of $155,250.00. Following the purchase, the chief executive officer now owns 7,900 shares of the company’s stock, valued at $49,059. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Shares of Nuvectra Corp (NASDAQ:NVTR) opened at 6.35 on Monday. The company’s market cap is $65.64 million. Nuvectra Corp has a 1-year low of $4.02 and a 1-year high of $9.95. The stock has a 50 day moving average price of $7.29 and a 200-day moving average price of $6.30.
Nuvectra Corp (NASDAQ:NVTR) last posted its quarterly earnings data on Tuesday, March 7th. The company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.89) by $0.38. The company earned $4.20 million during the quarter, compared to analysts’ expectations of $3.97 million. Nuvectra Corp had a negative return on equity of 33.89% and a negative net margin of 320.73%. The company’s revenue for the quarter was up 223.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.55) earnings per share. Equities research analysts forecast that Nuvectra Corp will post ($4.36) earnings per share for the current year.
Your IP Address:
Several large investors have recently bought and sold shares of NVTR. Laurel Wealth Advisors Inc. bought a new stake in Nuvectra Corp during the third quarter valued at approximately $914,000. FNY Partners Fund LP bought a new stake in Nuvectra Corp during the fourth quarter valued at approximately $429,000. Essex Investment Management Co. LLC bought a new stake in Nuvectra Corp during the third quarter valued at approximately $523,000. Hodges Capital Management Inc. raised its stake in Nuvectra Corp by 71.9% in the fourth quarter. Hodges Capital Management Inc. now owns 178,261 shares of the company’s stock valued at $897,000 after buying an additional 74,535 shares during the period. Finally, Palisade Capital Management LLC NJ acquired a new stake in shares of Nuvectra Corp during the third quarter worth about $453,000. Hedge funds and other institutional investors own 61.35% of the company’s stock.
NVTR has been the subject of several research analyst reports. Zacks Investment Research lowered Nuvectra Corp from a “buy” rating to a “hold” rating in a research note on Wednesday, January 11th. B. Riley reaffirmed a “buy” rating and set a $12.00 price target on shares of Nuvectra Corp in a research note on Wednesday, March 8th.
About Nuvectra Corp
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/insider-buying-nuvectra-corp-nvtr-ceo-buys-155250-00-in-stock/1708815.html
Receive News & Ratings for Nuvectra Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corp and related companies with MarketBeat.com's FREE daily email newsletter.